NextCure, Inc.

Stage 1 · Basing · week 9

As of Oct 22, 2026, NextCure is in Stage 1, the basing phase, now in week 9 (since Aug 24, 2026). It closed at $4.72, 66.9% below its 52-week high and below its 200-day average, which is falling.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. More about the company

$4.72

-12.83% today

$21.6M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is NXTC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 18w

S4 38w

S2 21w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 5w → S4 18w → S1 8w → S2 8w → S3 9w → S2 9w → S3 2w → S4 38w → S1 5w → S4 8w → S1 4w → S2 21w → S3 10w → S4 12w → S1 9w current

Total tracked: 165 weeks across 16 stage runs.

NXTC among Biotechnology392nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…392	NXTCNextCure, Inc.	Stage 1 · wk 9	19	−2.1%

vs 52W High

-66.9%

$1.60 lo$14.27 hi

66.9% below 52W high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 9

1w13w26w

Week 9, base building

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

-41.5%

200 DMA: $8.07 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.62x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↗

Short-term trend rising gently

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-2.1%

+11.3%

-61.9%

YTD

-64.5%

-60.0%

Scan Membership

Breakout Watch

Latest: 2024-07-18

5 appearances in last 60 days. First seen: 2020-02-24.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 9 · Vol 0.62x

2026-10-21S1

Wk 9 · Vol 0.61x

2026-10-20S1

Wk 9 · Vol 0.58x

2026-10-19S1

Wk 8 · Vol 0.46x

2026-10-16S1

Wk 8 · Vol 0.26x

2026-10-15S1

Wk 8 · Vol 0.47x

2026-10-14S1

Wk 8 · Vol 0.32x

2026-10-13S1

Wk 8 · Vol 0.32x

2026-10-12S1

Wk 7 · Vol 0.74x

2026-10-09S1

Wk 7 · Vol 0.45x

2026-10-08S1

Wk 7 · Vol 0.42x

2026-10-07S1

Wk 7 · Vol 0.55x

Moving averages & range

50 DMA

$6.27

200 DMA

$8.07

52W High

$14.27

52W Low

$1.60

5D Low

$4.72

Resistance levels (recent highs)

20d High

$7.18

60d High

$8.42

120d High

$10.72

250d High

$14.27

Next resistance

+52.1%

to 20d High

ROE

-204.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.6

NextCure: quick answers

What stage is NextCure in?

As of Oct 22, 2026, NextCure (NXTC) is in Stage 1, the basing phase. It entered Stage 1 on Aug 24, 2026 and is in week 9. What the four stages mean

Is NextCure in an uptrend?

Not yet. NextCure is in Stage 1, a base that can come before an uptrend. It trades 41.5% below its 200-day average, which is falling.

How far is NextCure from its 52-week high?

NextCure closed at $4.72 on Oct 22, 2026, 66.9% below its 52-week high of $14.27. Its 52-week low is $1.60.

How has NextCure performed over the past year?

As of Oct 22, 2026, NextCure is down 60.0% over the past year and down 64.5% so far in 2026.

Which sector and industry is NextCure in?

NextCure is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.